Pashtan et al. [39] reported that the simultaneous inhibition of Hsp90 and tyrosine kinase that reduces oncogene switching and drug resistance in breast cancer cells, which highlights targeting SLCO4A1-AS1 as an alternative strategy to inhibit both Cdk2 and Hsp90. Here, CDK2 is linked to breast cancer.